Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9.51B | 26.81%8.76B | 16.68%29.68B | 15.27%7.18B | 14.00%6.91B | 15.25%25.43B | 13.99%6.7B | 14.53%6.45B | 15.80%6.23B | 16.88%6.06B |
| Cost of revenue | 1B | 30.69%741M | 24.37%2.94B | 28.28%762M | 8.21%567M | 21.17%2.36B | 4.94%616M | 24.02%630M | 30.55%594M | 30.67%524M |
| Gross profit | 8.51B | 26.45%8.02B | 15.90%26.74B | 13.88%6.42B | 14.56%6.34B | 14.67%23.07B | 15.00%6.08B | 13.61%5.82B | 14.44%5.64B | 15.70%5.53B |
| Operating expense | 5.67B | 7.44%5.4B | 11.01%21.84B | 13.18%5.48B | 17.07%5.03B | 0.87%19.67B | 5.06%5.81B | 2.96%4.73B | -1.47%4.84B | -3.90%4.29B |
| Staff costs | --2.38B | 3.16%2.42B | 6.29%9.42B | 4.59%2.37B | 10.57%2.34B | 12.36%8.87B | 7.67%2.19B | 15.25%2.29B | 7.80%2.27B | 19.91%2.12B |
| Selling and administrative expenses | --1.7B | 16.84%1.49B | 23.57%6.55B | 32.41%1.59B | 28.99%1.28B | -28.89%5.3B | -13.96%2.01B | -31.13%1.1B | -36.63%1.2B | -39.15%990M |
| -Selling and marketing expense | --1.44B | 20.54%1.26B | 30.26%5.62B | 43.68%1.38B | 39.68%1.04B | -33.15%4.31B | -14.66%1.78B | -37.45%835M | -41.93%957M | -46.29%746M |
| -General and administrative expense | --257M | 0.43%236M | -5.68%930M | -12.50%210M | -3.69%235M | -1.40%986M | -8.20%235M | 0.75%267M | -0.41%240M | 2.52%244M |
| Research and development costs | --368M | 20.65%298M | 38.13%1.23B | 71.79%335M | 78.99%247M | 229.26%889M | 303.00%403M | 128.36%153M | 225.00%195M | 220.93%138M |
| Other operating expenses | --1.22B | 2.94%1.19B | 0.43%4.64B | 0.51%1.19B | 10.81%1.16B | 18.75%4.62B | 13.85%1.21B | 26.15%1.18B | 37.24%1.18B | 1.55%1.05B |
| Operating profit | 2.85B | 99.16%2.62B | 44.20%4.9B | 18.16%937M | 5.88%1.31B | 453.09%3.4B | 211.11%270M | 105.65%1.09B | 7,830.00%793M | 292.72%1.24B |
| Net non-operating interest income (expenses) | 6M | 600.00%7M | 100.00%6M | 2M | 150.00%1M | 113.64%3M | 137.50%3M | 133.33%2M | 0 | 0.00%-2M |
| Non-operating interest income | --6M | 600.00%7M | 20.00%6M | 100.00%2M | --1M | 400.00%5M | --2M | 100.00%2M | --1M | --0 |
| Non-operating interest expense | --0 | --0 | --0 | --0 | --0 | -91.30%2M | -112.50%-1M | --0 | -83.33%1M | 0.00%2M |
| Net investment income | 62M | -182.91%-97M | 222.47%287M | -2.44%80M | 875.00%117M | -70.13%89M | 49.11%-57M | -61.48%52M | -53.14%82M | -88.00%12M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | -80M | 33.33%-2M | 36.73%-31M | -1,400.00%-13M | -200.00%-3M | -1,533.33%-49M | 1M | -1M | ||
| Income from associates and other participating interests | ||||||||||
| Special income (charges) | 0 | 0 | -7,650.00%-155M | 94.44%-1M | 0 | 95.83%-2M | 92.68%-3M | 733.33%19M | -500.00%-18M | 0 |
| Less:Restructuring and mergern&acquisition | ---- | ---- | --150M | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Less:Other special charges | ---- | ---- | 120.00%3M | ---- | ---- | -850.00%-15M | --3M | ---21M | ---- | ---- |
| Less:Write off | --0 | --0 | -88.24%2M | -93.33%1M | --0 | -63.04%17M | --0 | -33.33%2M | 1,400.00%15M | --0 |
| Other non-operating income (expenses) | 4M | 25.00%5M | 96.74%181M | -25.00%15M | -60.00%4M | -9.80%92M | -4.92%58M | -75.00%4M | 900.00%20M | -56.52%10M |
| Income before tax | 2.83B | 76.84%2.53B | 46.80%5.18B | 15.93%1.02B | 13.68%1.43B | 276.12%3.53B | 164.06%221M | 74.26%1.17B | 396.61%879M | 189.63%1.26B |
| Income tax | 902M | 76.16%724M | 56.21%1.62B | 46.67%352M | 17.43%411M | 19.29%1.04B | 34.67%101M | 9.78%348M | -0.83%240M | 47.68%350M |
| Net income | 1.93B | 77.01%1.8B | 42.89%3.56B | 4.55%667M | 12.24%1.02B | 3,669.70%2.49B | 128.27%119M | 131.46%824M | 1,081.54%638M | 362.76%907M |
| Net income continuous operations | --1.93B | 77.11%1.8B | 42.87%3.56B | 4.38%667M | 12.24%1.02B | 3,614.93%2.49B | 128.57%120M | 131.83%823M | 1,083.08%639M | 360.41%907M |
| Noncontrolling interests | -52M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Net income attributable to the company | 1.99B | 77.01%1.8B | 42.89%3.56B | 4.55%667M | 12.24%1.02B | 3,669.70%2.49B | 128.27%119M | 131.46%824M | 1,081.54%638M | 362.76%907M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 1.99B | 77.01%1.8B | 42.89%3.56B | 4.55%667M | 12.24%1.02B | 3,669.70%2.49B | 128.27%119M | 131.46%824M | 1,081.54%638M | 362.76%907M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 42.94 | 82.33%39 | 43.41%74.99 | 4.55%14.01 | 12.11%21.39 | 3,506.21%52.29 | 127.37%2.51 | 123.23%17.3 | 1,043.66%13.4 | 344.76%19.08 |
| Diluted earnings per share | 42.94 | 82.33%39 | 43.41%74.99 | 4.53%14.0072 | 12.11%21.39 | 3,506.21%52.29 | 127.23%2.499 | 123.23%17.3 | 1,043.66%13.4 | 344.76%19.08 |
| Dividend per share | 0 | 0 | 114.29%30 | 0 | 0 | 7.69%14 | 7.69%14 | 0 | 0 | 0 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |